The FDA indicated it may approve the Moderna vaccine before Phase 3 clinical trials are completed, sparking debate over safety and public trust. Concerns are raised regarding the business model and long-term effects of DNA-influencing vaccines, which differ from traditional viral memory approaches. Speculation persists about whether such technology could lead to lasting genetic changes in human offspring.






